Ten abstracts providing new analyses of data from six major Phase III renal anemia studies for MIRCERA(R) will be presented at the upcoming 40th Annual Meeting of the American Society of Nephrology (ASN) in San Francisco on November 2 - 5, 2007.

Among the highlights will be new analyses from maintenance studies, including MAXIMA, PROTOS, STRIATA and RUBRA, and correction studies, including ARCTOS and AMICUS.

Please note all information presented at the ASN annual meeting is embargoed for media release until one hour after the time of presentation.

Abstracts accepted for the ASN annual meeting include:

-- Once-monthly intravenous (IV) C.E.R.A. maintains stable hemoglobin (Hb) in dialysis patients (pts), irrespective of age or gender. S. Fishbane et al. (SU-PO779. November 4: 10:00 a.m. - 12:00 p.m. PST. Exhibit Hall, Moscone Center)

-- Stable hemoglobin (Hb) levels are maintained with once-monthly C.E.R.A. in dialysis patients (pts), irrespective of mode of vascular access. F. Locatelli et al. (SU-PO822. November 4: 10:00 a.m. - 12:00 p.m. PST. Exhibit Hall, Moscone Center)

-- Once-monthly C.E.R.A. maintains stable hemoglobin (Hb) in patients (pts) with chronic kidney disease (CKD), irrespective of baseline iron levels. A. Nissenson et al. (SU-PO819. November 4: 10:00 a.m. - 12:00 p.m. PST. Exhibit Hall, Moscone Center)

-- C.E.R.A. maintains stable hemoglobin (Hb) in chronic kidney disease (CKD), regardless of albumin or dialysis adequacy (Kt/V). W. Sulowicz et al. (Publication Only)

-- Effect of baseline hemoglobin (Hb) on Hb stability in patients (pts) with chronic kidney disease (CKD) receiving once-monthly C.E.R.A. N.W. Levin et al. (SU-PO817. November 4: 10:00 a.m. - 12:00 p.m. PST. Exhibit Hall, Moscone Center)

-- Anemia correction with C.E.R.A. in patients (pts) with chronic kidney disease (CKD) is unaffected by baseline hemoglobin (Hb) level. R. Provenzano et al. (SU-PO796. November 4: 10:00 a.m. - 12:00 p.m. PST. Exhibit Hall, Moscone Center)

-- Median hemoglobin (Hb) decline following C.E.R.A. dose interruption is similar to that with other erythropoiesis stimulating agents (ESAs). P.

Barany et al. (SU-PO795. November 4: 10:00 a.m. - 12:00 p.m. PST. Exhibit Hall, Moscone Center)

-- Diabetes status and ethnicity do not alter efficacy of C.E.R.A. in patients with chronic kidney disease: analysis of 3 phase III trials. T. Golper et al. (SU-PO1019. November 4: 10:00 a.m. - 12:00 p.m. PST. Exhibit Hall, Moscone Center)

-- C.E.R.A. maintains hemoglobin in dialysis patients directly switched from epoetin (EPO) without increasing iron therapy requirements. A. Nissenson et al. (F-PO855. November 2: 10:00 a.m. - 12:00 p.m. PDT. Exhibit Hall, Moscone Center)

-- C.E.R.A. every 2 or 4 weeks maintains hemoglobin control in CKD patients on dialysis with and without congestive heart failure: pooled Phase III analysis. S. Fishbane et al. (F-PO843. November 2: 10:00 a.m. - 12:00 p.m. PDT. Exhibit Hall, Moscone Center)

About MIRCERA

The clinical program for MIRCERA consisted of 10 global studies involving more than 2,700 patients from 29 countries. The Phase III program for MIRCERA included two correction studies and four maintenance studies exploring intravenous (IV) and subcutaneous (SC) MIRCERA at extended administration intervals.

MIRCERA has a longer half-life than any commercially available erythropoiesis-stimulating agent (ESA). In clinical trials MIRCERA corrected anemia in chronic kidney disease (CKD) patients with dosing once every two weeks and maintained hemoglobin levels in CKD patients with dosing intervals up to once monthly. In the U.S., the FDA is completing its review and MIRCERA is anticipated to be approved mid-November.

Safety Information

MIRCERA has a demonstrated safety profile comparable to other erythropoietic agents.

The most commonly reported adverse events in the MIRCERA Phase II/III clinical program were hypertension, nasopharyngitis, diarrhea, headache, and upper respiratory tract infection.

Erythropoietic therapies increase the risk of death and serious cardiovascular and thromboembolic events when administered to a hemoglobin of greater than 12 g/dL. A rate of Hb rise of >1 g/dL over 2 weeks may also contribute to these risks.

Erythropoiesis stimulating agents, when administered to target a hemoglobin of greater than 12 g/dL, have shortened the time to tumor progression, shortened survival and increased the risk of death in cancer patients.

Pure Red Cell Aplasia (PRCA) has been observed in patients treated with erythropoietin therapy. However, PRCA has not been observed with MIRCERA in clinical trials to date.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and quality of life. An employer of choice, in 2007 Roche was named Top Company of the Year by Med Ad News and one of the Top 20 Employers (Science magazine). In 2006, Roche was ranked the No. 1 Company to Sell For (Selling Power), and one of AARP's Top Companies for Older Workers, and in 2005, Roche was named one of Fortune magazine's Best Companies to Work For in America. For additional information about the U.S. pharmaceuticals business, visit our websites: rocheusa or roche.us.

All trademarks used or mentioned in this release are protected by law.

Roche
rocheusa

View drug information on Mircera.

Tag Cloud